1. Home
  2. OBAI vs PASG Comparison

OBAI vs PASG Comparison

Compare OBAI & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OBAI

TG-17 Inc. Common Stock

N/A

Current Price

$0.53

Market Cap

25.2M

ML Signal

N/A

PASG

Passage Bio Inc.

HOLD

Current Price

$4.35

Market Cap

26.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBAI
PASG
Founded
2017
2017
Country
United States
United States
Employees
N/A
27
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
26.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
OBAI
PASG
Price
$0.53
$4.35
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$14.00
AVG Volume (30 Days)
1.4M
120.5K
Earning Date
05-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.28
52 Week High
$19.95
$20.00

Technical Indicators

Market Signals
Indicator
OBAI
PASG
Relative Strength Index (RSI) 21.65 30.29
Support Level $0.44 N/A
Resistance Level $1.66 $7.76
Average True Range (ATR) 0.10 0.66
MACD 0.10 -0.37
Stochastic Oscillator 18.73 1.16

Price Performance

Historical Comparison
OBAI
PASG

About OBAI TG-17 Inc. Common Stock

Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions.

About PASG Passage Bio Inc.

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Share on Social Networks: